- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04104360
Galacto-oligosaccharides and Intestinal Activity
September 25, 2023 updated by: Maastricht University Medical Center
Impact of Galacto-oligosaccharides on the Intestinal Microbial Composition and -Activity: a Proof of Concept Study
Dietary intake of galacto-oligosaccharides (GOS) may have beneficial effects on host health by affecting the microbiota composition and -activity.
So far studies focused on analyses in fecal samples, while the primary site of carbohydrate fermentation is the proximal colon.
To date, no studies have been performed in humans on the more proximal microbiota and the impact of fermentable carbohydrates.
Further insights on the more proximal colonic microbiota would aid to targeted approaches to improve intestinal health.
Therefore, we aim to study the effect of GOS on the intestinal microbiota composition and -activity in healthy adults, by sampling the more proximal human colon in a physiological condition.
The primary objective of this study is to investigate the impact of four weeks GOS supplementation on intestinal microbiota composition and -activity, by sampling the proximal part of the human colon in a physiological condition.
Furthermore, this study has four secondary objectives: First, to compare the intestinal microbiota composition and -activity of the proximal colon vs. distal colon at baseline and after four weeks GOS supplementation.
Second, compare the luminal microbiota composition vs. mucosa adherent microbiota composition of the proximal vs. distal colon at baseline and after four weeks GOS supplementation.
Third, monitor the effects of four weeks GOS supplementation on gastrointestinal symptoms.
The study conforms to a randomized, double-blind, placebo-controlled, parallel design.
Study population includes healthy human volunteers (male and female), 18-50 years of age.
One intervention arm will include 7.2 grams of Vivinal® GOS Powder three times daily for four weeks.
The other intervention arm subjects will receive placebo product (7.2 grams maltodextrin) three times daily for four weeks.
At the start and end of the intervention period, several measurements will take place.
The main study parameter is the change in microbial composition and -activity induced by GOS intervention.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: L. ME Kuin, MD
- Phone Number: +31 88 388 7271
- Email: gaia-intmed@maastrichtuniversity.nl
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 HX
- Recruiting
- Maastricht University Medical Center
-
Contact:
- L. Kuin, MD
- Phone Number: +31 88 388 7271
- Email: gaia-intmed@maastrichtuniversity.nl
-
Principal Investigator:
- D. Keszthelyi, Professor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Based on medical history no gastrointestinal complaints can be defined.
- Regular stool frequency ranging from 3 times/day - 3 times/week.
- Body Mass Index (BMI) ≥ 20 and < 30 kg/m2.
- Weight-stable for at least 90 days prior to participation (no change in bodyweight, i.e. < 3kg).
- Willing to be informed in case of unexpected findings.
Exclusion Criteria:
- History of any disease or surgery interfering with the study aims, limiting participating or completing the study protocol.
- Self-admitted human immunodeficiency virus-positive state.
- Disease with a life expectancy shorter than 5 years.
- Abdominal surgery interfering with gastrointestinal function, upon judgment of the medical doctor, who will decide on in- or exclusion based on the surgery applied.
- Use of antibiotics within 90 days prior to the study.
- Use of anticoagulation medication (except Ascal).
- Use of proton pump inhibitors.
- Use of other medication will be reviewed by a medical doctor, who will decide on in- or exclusion based on the drug(s) used.
- Last colonoscopy within 90 days prior to the study.
- Inadequate or painful (self-reported) colonoscopy undergone in the past.
- American Society of Anesthesiologists (ASA) classification > 2.
- Smoking.
- Pregnancy or lactation.
- Plan to lose weight or follow a specific diet within the study period.
- Alcohol intake >14 units/week.
- Use of laxatives within 14 days prior to the study.
- Drug use.
- Administration of probiotic or prebiotic supplements, investigational drugs or participation in any scientific intervention study, which may interfere with this study (to be decided by the principle investigator), in the 14 days prior to the study.
- History of side effects towards intake of prebiotic supplements.
- Self-admitted lactose intolerance.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Galacto-oligosacchardies
During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
|
During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
|
Placebo Comparator: Maltodextrin
During this period subjects will receive 7.2 grams of maltodextrin three times daily for four weeks
|
During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbial composition, as determined by state of the art (e.g. HiSeq) sequencing of 16S rRNA genes in colonic luminal/fecal samples and biopsies.
Time Frame: Change from baseline to four weeks supplementation
|
Total DNA will be extracted from fecal, small intestinal fluid and biopsy samples using the repeated bead-beating method.
This method has been optimized and standardized for the extraction of total bacterial DNA from human fecal samples.
Isolated DNA will be used for amplification of the V4 region of the collective 16S rRNA genes using barcoded primers, while fecal and intestinal DNA as target.
Afterwards, the NG-Tax pipeline will be used for microbiota profiling.
A variety of programs, such as R, and in house scripts will be used for bioinformatics analyses and multivariate statistics.
|
Change from baseline to four weeks supplementation
|
Microbial activity as determined by metatranscriptomics using RNA in colonic luminal samples and biopsies.
Time Frame: Change from baseline to four weeks supplementation
|
Microbiota activity profiling will be performed by metatranscriptomics.
In short, RNA will be isolated from the luminal samples, followed by removal of rRNA and subsequent conversion of residual RNA into cDNA.
The cDNA will serve as target for paired-end HiSeq sequencing.
Obtained sequence reads will be phylogenetically and functionally annotated as described before.
Dedicated R-scripts as well as programs such as iPath will be used for bioinformatic analyses, including metabolic mapping, and interpretation to determine which bacterial group is performing what activities.
In addition, key metabolites of saccharolytic and protein fermentation (such as (branched) chain fatty acids) will be assessed by High-performance liquid chromatography (HPLC).
|
Change from baseline to four weeks supplementation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: D. Keszthelyi, MD, PhD, Maastricht University Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 17, 2019
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
September 17, 2019
First Submitted That Met QC Criteria
September 23, 2019
First Posted (Actual)
September 26, 2019
Study Record Updates
Last Update Posted (Actual)
September 26, 2023
Last Update Submitted That Met QC Criteria
September 25, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 18-039
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Adults
-
KU LeuvenCompletedHealthy Older Adults | Ill Older AdultsBelgium
-
Samsung Medical CenterTerminatedHealthy Aging | Healthy AdultsKorea, Republic of
-
King Abdulaziz UniversityUniversity College Dublin; Royal College of Surgeons, IrelandRecruitingHealthy Adults | Healthy NutritionSaudi Arabia
-
Lumos Labs, Inc.Not yet recruitingHealthy AdultsUnited States
-
Shirley Ryan AbilityLabNot yet recruiting
-
National Institute of Allergy and Infectious Diseases...RecruitingHealthy AdultsUnited States
-
Arizona State UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingHealthy AdultsUnited States
-
Marian NeuhouserDuke University; University of Washington; University of Nebraska; United States...Recruiting
-
Mirati Therapeutics Inc.CompletedHealthy AdultsUnited States
-
Ohio State UniversityActive, not recruitingHealthy AdultsUnited States
Clinical Trials on Galacto-oligosaccharides
-
OlygoseInstitute of Cardiometabolism and Nutrition, FranceCompletedRandomized Versus Placebo | Controlled | Double BlindFrance
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteNot yet recruitingIntestinal HealthUnited States
-
University of SurreyFrieslandCampinaRecruitingAnxiety | Gamma-Aminobutyric Acid | Glutamate | Emotion Regulation AbilitiesUnited Kingdom
-
Wageningen UniversityUniversity Medical Center GroningenCompletedMetabolism | Dietary Fiber | IntestineNetherlands
-
Clasado Biosciences LtdWithdrawnTraveler's Diarrhea
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
University of California, DavisEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedFecal Microflora in the Formula Fed Premature InfantUnited States
-
Wageningen UniversityUnknown
-
South Dakota State UniversitySanford HealthUnknown
-
Swiss Federal Institute of TechnologyUniversity of StellenboschRecruitingHIV | Iron DeficiencySouth Africa